We conducted a secondary analysis of data from the Prevention of Recurrent Episodes of
Depression With Venlafaxine Extended Release (ER) for Two Years (PREVENT) trial to …

BACKGROUND: The degree of agreement between patient-and clinician-rated scales of
depressive severity varies widely. This study analyzed agreement between commonly used …

Background: This article develops and applies depression-free days (DFDs) as a summary
measure of the temporal pattern of response and remission in a comparison of venlafaxine …

OBJECTIVE: Predicting treatment outcome at an early stage is clinically relevant. The main
objectives are: to compare rates of remission after acute and continuation phase treatment …

Moderators are baseline variables that predict response to a treatment. Prognostic
moderators predict response to all treatments, whereas prescriptive moderators predict …

BACKGROUND: Delayed onset of efficacy of antidepressants and a high proportion of
depressed patients being poor or non-responders to antidepressants are well known clinical …

Background Goals of treating major depressive disorder (MDD) include achieving remission
and avoiding relapse. It is possible that patients may have a broader view of remission than …

The goal of treatment for major depressive disorder is remission, but many patients do not
achieve complete remission, and few reach sustained remission (ie, recovery). However …

Objective: The goal of treating major depressive disorder (MDD) should be not only
achieving remission in a particular episode but also avoiding relapses and attaining long …

Background Research so far provided few clues on the order in which depressive symptoms
typically remit during treatment. This study examined which depressive symptoms improve …